SCHEMBL4382926

SCHEMBL4382926

O=c1[nH]ccc2c1CCN2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.42
GRIA1 P42261 1/20 0.42
GRIA2 P42262 1/20 0.42
GRIA3 P42263 1/20 0.42
GRIA4 P48058 1/20 0.42
MAP2K1 Q02750 2/20 0.40
CRBN Q96SW2 1/20 0.35
PARP10 Q53GL7 4/20 0.34
PARP11 Q9NR21 4/20 0.34
PARP1 P09874 3/20 0.34
MEN1 O00255 2/20 0.34
HPGD P15428 2/20 0.34
HTT P42858 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103933 0.88 GRIA1 (0.56) NOTUMGRIA1GRIA2GRIA3GRIA4
SCHEMBL5655667 0.80 NOTUM (0.41) NOTUMGRIA1GRIA2GRIA3GRIA4
SCHEMBL7872035 0.68 NOTUM (0.44) NOTUMGRIA1GRIA2GRIA3GRIA4
SCHEMBL16064614 0.68 CD44 (0.46) MEN1KMT2ACYP2C19
SCHEMBL31310076 0.67 MAP2K1 (0.40) MAP2K1CRBNPARP10PARP11PARP1
SCHEMBL14145713 0.67 MAP2K1 (0.40) MAP2K1CRBNPARP10PARP11PARP1
SCHEMBL16101456 0.67 PARP1 (0.32) PARP1
SCHEMBL4952443 0.64 AURKA (0.32) PARP1
SCHEMBL29850336 0.64 PNMT (0.46) PARP1
SCHEMBL1701630 0.64 ACHE (0.56) NOTUMPARP1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008030119-A9 ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES INDUSTRIAL RESEARCH LIMITED (NZ) 2009-09-24 WO claimed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20230322767-A1 ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF THE BROAD INSTITUTE, INC. 2023-10-12 US disclosed
EP-4188551-A1 ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF Bayer Aktiengesellschaft (DE) 2023-06-07 EP disclosed
US-10301306-B2 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2019-05-28 US disclosed
WO-2016100166-A1 SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2016-06-23 WO disclosed
EP-2661438-A2 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS Hanmi Pharm. Co., Ltd. (KR) 2013-11-13 EP disclosed
WO-2012093809-A2 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS HANMI PHARM CO., LTD. (KR) 2012-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301306-B2 Substituted dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-ones as RIPK3 inhibitors RIPK3, RIPK1, RIPK4 NOTUM 4142/4885GRIA1 1214/4885GRIA2 1642/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 NOTUM 4563/4885GRIA1 540/4885GRIA2 983/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B NOTUM 734/4885GRIA1 4440/4885GRIA2 4486/4885
US-20230322767-A1 ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF PNPO, THPO, PAH NOTUM 4353/4885GRIA1 2013/4885GRIA2 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.